Understanding the effects of the tumour growth environment on Chk1 signalling and sensitivity to small molecule Chk1 inhibition as well as differences in DDR pathway signalling between the in vitro and in vivo context is important for guiding the clinical evaluation of Chk1 inhibitors. The gene discussed is CHEK1; the disease is neoplasm.